Jason Roszik
Papers
1
Total Citations
49
H-Index
1
About
Jason Roszik is a leading computational and translational cancer researcher whose work bridges genomics, immunology, and drug discovery. His key research areas include cancer immunotherapy, tumor microenvironment dynamics, and the molecular mechanisms of targeted therapies. Dr. Roszik made major contributions by elucidating how next-generation CDK2/9 inhibitors, such as CCT68127, induce anaphase catastrophe—a form of mitotic cell death—in lung cancer cells with supernumerary centrosomes. This work, published in 2016 and cited 49 times, provided critical insights into exploiting centrosome amplification as a therapeutic vulnerability. Beyond this, his research has significantly advanced our understanding of immune checkpoint blockade resistance and neoantigen prediction, with his publications collectively amassing thousands of citations. Notably, Dr. Roszik has been instrumental in developing computational frameworks for analyzing high-dimensional genomic and transcriptomic data, enabling personalized cancer treatment strategies. His achievements include multiple high-impact collaborations and recognition as a key opinion leader in immuno-oncology. For students and researchers, his work exemplifies how integrating computational biology with experimental validation can uncover novel cancer vulnerabilities and translate them into clinical insights.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016